Member Info for Leistertheinvestor

He’s a repeat offender, if you’re losing money with this CEO it’s on you.

It literally mentions it in the RNS..

I agree, a change of CEO is a very positive move, new energy, ideas and experience.

New ceo is currently under financial sanction (he’s appealing it) for disclosing market sensitive information.. he may be very quiet to begin with.

All the best to Nigel, enjoy your retirement.

Some would argue he’s failed but there’s not many other companies that’s achieved these kind of results orally on a shoestring budget.. Nuvec isn’t dead, it just needs some serious funding to accelerate and keep the market engaged.

Sweet FA for two years? Delivering two separate RNA compounds inside the gut, and getting the correct responses!?

Admittedly it seems a never ending struggle to get commercial success but that’s pre-clinical pharma for you, it’s never been any different.

Might exceed the normal ISA allowance unless it’s Rachel from accounts making another miscalculation.

They can only sell once…

Your first and second post are totally pointless, correct decision to delete it.

Pumpkys comments are designed to look after pumpkys trading style, anyone pumping a stock to get a better exit point is cut from the same cloth.

It’s a great start to the week :)

That was a great reply to be fair :)

Wouldn’t want to guess the buy/sell on that trade.

I think we’re at a stage when the bod tells us the type of tests they’re conducting to gather the data required to encourage commercial discussion. Personally I’m very interested to know the systemic implications for Nuvec during and after administration, I believe outside eyes will also be keen to have this info, yesterday!

Looks ready to stretch its legs.

I’m out. For now.

Will definitely add back if I see that obvious big buying before news.

Just had a little top up myself :)

Genuinely thought we’d of seen some volume coming in around now, it’s not looking too great is it.

Will continue to hold just in case.

I don’t believe they’ll be able to fully market the abilities of the dual loaded technology for the IBD model until the patent is approved.

The most important thing is protection, that comes before talking to industry leaders.

They have a novel delivery system that’s able to deliver TWO nucleic acid compounds in one delivery system, orally and in the gut..if they ever emulate this in man it’s a knockout punch.

The investment community may not recognise this achievement but the right companies will be aware.

So many commentators is a real red flag that put's off potential buyers. It looks desperate and I genuinely think it’s counterproductive.

This could have gone crazy today.

We had a director buy last time it did this.

I repeat- as they’ve honestly laid out to us, everything is in RNS and everything is assuming to complete unless stated in a new RNS.

Given a director has invested another 2.5m shares totalling £36,000 taking his overall holding 9.11m shares, we’ll assume he’s not a dimwit looking to throw away capital he could have invested elsewhere.